

TABLE I. Clinical Stage T1c (nonpalpable, PSA elevated)

PSA Range (ng/mL)		Pathologic Stage	Gleason Score					
			2-4	5-6	3+4=7	4+3=7	8-10	
Clinical Stage:	T1c	0-2.5	Organ confined	95 (89-99)	90 (88-93)	79 (74-85)	71 (62-79)	66 (54-76)
PSA Value:	32.4		Extraprostatic extension	5 (1-11)	9 (7-12)	17 (13-23)	25 (18-34)	28 (20-38)
Gleason Score:	5-6		Seminal vesicle (+)	—	0 (0-1)	2 (1-5)	2 (1-5)	4 (1-10)
			Lymph node (+)	—	—	1 (0-2)	1 (0-4)	1 (0-4)
Submit		2.6-4.0	Organ confined	92 (82-98)	84 (81-86)	68 (62-74)	58 (48-67)	52 (41-63)
Profile :			Extraprostatic extension	8 (2-18)	15 (13-18)	27 (22-33)	37 (29-46)	40 (31-50)
			Seminal vesicle (+)	—	1 (0-1)	4 (2-7)	4 (1-7)	6 (3-12)
			Lymph node (+)	—	—	1 (0-2)	1 (0-3)	1 (0-4)
Clinical Stage	T1c	4.1-6.0	Organ confined	90 (78-98)	80 (78-83)	63 (58-68)	52 (43-60)	46 (36-56)
Gleason Score	5-6		Extraprostatic extension	10 (2-22)	19 (16-21)	32 (27-36)	42 (35-50)	45 (36-54)
PSA	32.4		Seminal vesicle (+)	—	1 (0-1)	3 (2-5)	3 (1-6)	5 (3-9)
Recurrence Risk :			Lymph node (+)	—	0 (0-1)	2 (1-3)	3 (1-5)	3 (1-6)
		6.1-10.0	Organ confined	87 (73-97)	75 (72-77)	54 (49-59)	43 (35-51)	37 (28-46)
			Extraprostatic extension	13 (3-27)	23 (21-25)	36 (32-40)	47 (40-54)	48 (39-57)
Seminal vesicle (+)	—		2 (2-3)	8 (6-11)	8 (4-12)	13 (8-19)		
Lymph node (+)	—		0 (0-1)	2 (1-3)	2 (1-4)	3 (1-5)		
Pathological Stage :		>10.0	Organ confined	80 (61-95)	62 (58-84)	37 (32-42)	27 (21-34)	22 (16-30)
			Extraprostatic extension	20 (5-39)	33 (30-36)	43 (38-48)	51 (44-59)	50 (42-59)
			Seminal vesicle (+)	—	4 (3-5)	12 (9-17)	11 (6-17)	17 (10-25)
			Lymph node (+)	—	2 (1-3)	8 (5-11)	10 (5-17)	11 (5-18)

KEY: PSA = prostate-specific antigen.